Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC CLL 2026 | When to refer patients with CLL progressing on covalent BTK inhibitors for clinical trials

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses when community patients with chronic lymphocytic leukemia (CLL) who progress on a covalent BTK inhibitor should be referred to a tertiary center for clinical trials. Dr Davids explains that patients should be considered for a trial if they are interested and eligible, with ongoing Phase III trials comparing pirtobrutinib with BTK degraders as a good option. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

As we saw in the BRUIN CLL-322 trial, patients who are progressing on a covalent BTK inhibitor have pretty aggressive CLL at that point. So I think all of these patients, if they’re interested and potentially eligible for a clinical trial, should be referred for consideration of a trial. It’s not that a trial would be right for every patient, but I do think that many patients could benefit, and we still need to learn more about how best to treat these patients...

As we saw in the BRUIN CLL-322 trial, patients who are progressing on a covalent BTK inhibitor have pretty aggressive CLL at that point. So I think all of these patients, if they’re interested and potentially eligible for a clinical trial, should be referred for consideration of a trial. It’s not that a trial would be right for every patient, but I do think that many patients could benefit, and we still need to learn more about how best to treat these patients. A good example is the Phase III trials that are ongoing, directly comparing pirtobrutinib to BTK degraders. For a patient progressing on a frontline covalent BTK inhibitor, I think a trial like that is a great option, because if they’re randomized to pirtobrutinib, that’s probably what they would be getting anyway. If they’re randomized to a BTK degrader, we think these are very promising drugs and maybe better than pirtobrutinib in that context, but we don’t know yet, and that’s why the trials are ongoing.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.